Trontier 2: A phase 3, multicenter randomized double-blind, placebo-controlled, parallel-group efficacy and safety study of Trontinemab in participants with early symptomatic Alzheimer’s disease (MCI to mild dementia due to AD). Aged 50-90 years, MMSE >21 up to 18 months of trial related activities.
Novartis CVHB: A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer’s Disease followed by an extension. Aged 50-85 years, CDR 0.5 or 1 and ADAS-cog 13-54, up to 18 months of trial related activities with a long-term extension offered.
SELENATE: A phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probable Behavioural Variant Fronto-temporal Dementia. Aged >35 years, 1 year of trial related activities.
Uplift-D: A phase 1B open-label, multicenter, dose escalation study to assess the safety, tolerability and pharmacodynamic effects of a single dose of PBFT02 delivered into the cisterna magna (ICM) of adult participants with frontotemporal dementia (FTD) and mutations in the granulin precursor (GRN) or chromosome 9 open reading frame 72 (C9orf72) genes. Aged 35- 75 years, CDR 0.5-1, 5 years of trial related activities.
NAVAIDD Study: Neurofilament light chain And Voice Acoustics In Dementia Diagnosis. A cohort study to assess the diagnostic utility of plasma neurofilament light chain in all cause dementia. This study is including anyone attending Eastern health with a cognitive complaint.
Click on the video for more information.
Click on a link below to view this video in your language.